- cafead Nov 07, 2018 at 07:12: PM
via Shares of Myriad Genetics (NASDAQ: MYGN) fell over 10% today after the company reported fiscal first-quarter 2019 operating results. The business crushed Wall Street estimates for adjusted earnings per share and exactly matched quarterly revenue expectations, but caused a stir by reducing its fiscal full-year 2019 revenue guidance just three months into the new operating year.
article source
article source